We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SymBio Announces Bendamustine Hydrochloride (SyB L-0501) Launch in Taiwan
Product News

SymBio Announces Bendamustine Hydrochloride (SyB L-0501) Launch in Taiwan

SymBio Announces Bendamustine Hydrochloride (SyB L-0501) Launch in Taiwan
Product News

SymBio Announces Bendamustine Hydrochloride (SyB L-0501) Launch in Taiwan


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SymBio Announces Bendamustine Hydrochloride (SyB L-0501) Launch in Taiwan"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SymBio Pharmaceuticals Limited has announced that its licensing partner, InnoPharmax, Inc. has launched bendamustine HCl (SyB L-0501) under the trade name Innomustine® in Taiwan for the treatment of chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin’s lymphoma (NHL) as monotherapy in patients.

InnoPharmax received approval of its New Drug Application (NDA) for bendamustine HCl (SyB L-0501) from the Taiwan Food and Drug Administration (TFDA) in October, 2011.

In Japan, SymBio received market approval of bendamustine HCl (SyB L-0501) under the trade name TREAKISYM® in October, 2010, and launched the drug in December for the treatment of patients with refractory/relapsed low grade non-Hodgkin’s lymphoma and mantle cell lymphoma.

Working with Eisai Co. Ltd., TREAKISYM® has achieved rapid market penetration in Japan.

SyB L-0501 is being marketed in other Asia Pacific countries after receiving market approvals in Hong Kong (December, 2009) and Singapore (January, 2010) for the treatment of patients with low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia, and in South Korea (May, 2011) for the treatment of patients with chronic lymphocytic leukemia and multiple myeloma.

Aspiring to be a leading oncology specialty Pharma in Asia Pacific, SymBio's business in key Asian markets continues to expand as it nimbly develops and commercializes SyB L-0501 in the hematology space to address the underserved medical needs of patients.

Advertisement